Navigation Links
The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
Date:8/30/2007

LAUSANNE, Switzerland, August 30 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, today presented the 'Debiopharm Life Sciences Award' to Hungarian scientist Dr Zoltan Nusser for his outstanding research in both fundamental and clinical neuroscience. Funded by Debiopharm and organised by the Ecole Polytechnique Federale de Lausanne (EPFL), the ceremony took place during the EPFL Life Science Symposium 2007. Dr Nusser and his institute received CHF 100'000 and an etched crystal tribute commemorating this honour.

"We were impressed with the quality of research conducted by Dr Nusser," said Rolland-Yves Mauvernay, President of Debiopharm Group. "And more importantly, his work could be applied to drugs that would make a difference to the lives of patients."

"The Debiopharm Life Sciences Award 2007 underscores the spectacular progress we have made in understanding the fundamental mechanisms involved in sensorial perception," added Patrick Aebischer, President of EPFL.

Dr Nusser's work, at the Hungarian Academy of Sciences of Budapest, focuses on understanding the sub cellular organisation and function of synapses in the central nervous system (CNS) and their involvement in neuronal network activities underlying sensory perception. The application of his research could lead to the development of new treatments for patients suffering from CNS diseases. He has received various prizes and has published his research in leading publications including Nature, Neuron and Proceedings of the National Academy of Sciences (PNAS).

About the Debiopharm Life Sciences Award

The Award was set up to mentor and motivate young innovative European researchers in the field of life sciences. Criteria for applications include novelty and originality of the work, as well as its importance and significance in connection with targeted therapeutic fields.

Debiopharm also presents the 'Debiopharm-CCRF China Award' in China; and the 'JCA-Mauvernay Award' in Japan.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.6 billion in 2006.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com.

Debiopharm S.A. Contacts

Kim Bill

VP, Business Development &

Licensing

Tel.: +41-(0)21-321-01-11

Fax: +41-(0)21-321-01-69

kbill@debiopharm.com

Additional Media Contacts

In London

Maitland

Brian Hudspith

Tel: +44-(0)20-7379-5151

bhudspith@maitland.co.uk

In New York

Russo Partners, LLC

Wendy Lau

Tel: +1-212-845-4272

Fax: +1-212-845-4260

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE The Debiopharm Group
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Automation of the Eppendorf Perfectprep BAC 96 DNA Kit on the Caliper Life Sciences Sciclone ALH 3000
2. Perscitus Biosciences secures $250K Commerce loan
3. Wisconsin biosciences rise to the challenge
4. Wisconsin professors elected to National Academy of Sciences
5. Quintessence Biosciences advances cancer drug
6. Quintessence Biosciences names new president
7. InvivoSciences receives NIH grant for heart technology
8. Caden Biosciences may signal critical mass
9. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
10. QBI Life Sciences snags $130,000 NIH grant
11. WARF signs licensing pact with BD Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/13/2018)... ... November 12, 2018 , ... AseptiScope(TM), Inc. ... two large U.S. studies, published last week, confirm pose a significant health risk. ... Control (AJIC) conclude that stethoscopes are often improperly or rarely disinfected. In the ...
(Date:11/13/2018)... ... November 13, 2018 , ... Aditya Humad, Managing Partner of ... that asserts it is still trending upward with growing valuations based on a ... market consolidation, pricing pressure and increased competition as reasons often cited by institutional ...
(Date:11/13/2018)... ... November 13, 2018 , ... Sharon Kleyne, founder ... in Grants Pass, Oregon believes in the power of talk radio education Power ... Science® sponsors the Power of Water® on talk radio every week with the ...
(Date:11/9/2018)... ... November 08, 2018 , ... ... PhD, co-Founder, Chief Executive Officer and President of Andes Biotechnologies, to its Scientific ... world, Dr. Valenzuela brings to uBiome expertise on the genetic studies of hepatitis ...
Breaking Biology Technology:
(Date:12/5/2018)... TUCSON, Ariz. (PRWEB) , ... December 04, 2018 ... ... Dr. Kenneth Choi has been designated as a UroLift® Center of Excellence. The ... experience with the UroLift System and demonstrated a commitment to exemplary care for ...
(Date:11/29/2018)... ... November 29, 2018 , ... ... with the intention of acquiring full ownership. The transaction was approved by the ... on November 14, 2018. “We are extremely pleased to team up with Tosoh ...
(Date:11/27/2018)... Calif. (PRWEB) , ... November 27, 2018 , ... ... Sons. The companies have worked together to integrate the LabArchives Classroom Edition ... The combined offering will be available beginning January of 2019. ...
Breaking Biology News(10 mins):